|Table of Contents|

The clinical effects of S-1 on the maintenance therapy of advanced nasopharyngeal carcinoma patients after first-line treatment

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 02
Page:
197-201
Research Field:
Publishing date:

Info

Title:
The clinical effects of S-1 on the maintenance therapy of advanced nasopharyngeal carcinoma patients after first-line treatment
Author(s):
Wei Min1; Lei Yong2; Shao Chengze2; Liang Gai2; Du Wei2
1.Department of Oncology,The Seventh Affliated Hospital,Sun Yat-Sen University,Guangdong Shenzhen 518107,China;2.Department of Oncology,Jingzhou First People's Hospital，The First Affliated Hospital of Yangtze University,Hubei Jingzhou 434000,China.
Keywords:
S-1; advanced nasopharyngeal carcinoma; maintenance treatment
PACS:
R739.6
DOI:
10.3969/j.issn.1672-4992.2018.02.010
Abstract:
Objective:To investigate the curative effects of S-1 on the maintenance therapy after first-line treatment of patients with advanced nasopharyngeal carcinoma.Methods:We selected 58 cases of patients with advanced nasopharyngeal carcinoma admitted in our hospital from January 2012 to December 2014.All the patients had first-line treatment for 4~6 cycles and get CR,PR,SD.Then they were divided into the observation group and control group.Patients in observation group were treated with S-1，and those in control group did not have S-1 treatment.The overall survival time（OS),progression free survival time(PFS),total efficacy as well as incidence of adverse reactions were observed and compared between the two groups.Results:The objective response rates（RR) in the observation group and the control group were 80.0% and 35.7%,respectively.The control group had the progression-free survival time of 4.8 months［95% confidence interval（CI) of 3.8~5.8 months］ and the median survival time of 12.3 months（95%CI of 8.7~15.9 months).The observation group had the progression-free survival time of 9.6 months（95%CI of 8.5~10.7 months) and the median survival time of 18.8 months（95%CI of 15.7~21.9 months).The observation group had the both longer than the control group（P＜0.05).The observation group had significantly higher incidence rates of leukemia,gastrointestinal reaction,oralmucositis than the control group（P＜0.05),but the patient can tolerate.Conclusion:S-1 used in the maintenance therapy after first-line treatment could effectively prolong the survival time of patients with advanced nasopharyngeal carcinoma and improve the curative effect.The adverse actions may be tolerated,and it is worthy of further study.

References:

[1]Terret C,Albrand G,Moncenix G,et al.Karnofsky performance scale(KPS) or physical performance test(PPT) that is the question［J］.Critical Reviews in Oncology/Hematology,2011,77(2):142-147.
[2]Yi Junlin,Gao Li,Huang Xiaodong,et al.The failure patterns of nasopharyngeal carcinoma treated by radiation therapy［J］.Chin J Radiat Oncol,2004,13(3):145-148.［易俊林,高黎,黄晓东,等.鼻咽癌放射治疗的失败模式［J］.中华放射肿瘤学杂志,2004,13(3):145-148.］
[3]Chan AT.Nasopharyngeal carcinoma［J］.Ann Oncol,2010,21(Suppl 7):308-312.
[4]Cai Yuecheng，Ye Jinhui，He Baozhen.Comparison of the effect of paclitaxel and 5-fluorouracil combined with cisplatin in the treatment of liver and lung metastasis tumors from advanced nasoplaryngeal carcinoma［J］.Journal of Tropical Medicine,2006,2(6):156-158.［蔡悦成,叶金辉,何宝贞.TP与DF化疗方案治疗鼻咽癌肝、肺转移的疗效比较［J］.热带医学杂志,2006,2(6):156-158.］
[5]Hoff PM.Thetegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines,UFT/leucovorin（ORZEL) and S-1:A review of their clinical development and therapeutic potential［J］.Invest New Drugs,2000,18(4):331-342.
[6]Boku N,Yamamoto S,Fukuda H,et al.Fluoronracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer:A randomised phase 3 study［J］.Lancet Oncol,2009,10(11):1063-1069.
[7]Tsushima T,Hironaka S,Boku N,et al.Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer［J］.Gastric Cancer,2010,13(4):245-250.
[8]Emi M,Yamaquchi Y,Hihara J,et al.Phase I trial ofoxaliplatin plus S-1 chemotherapy in patients with metastatic colorectal cancer［J］.Oncol Lett,2010，1(1):95-98.
[9]Horio T,Tsujimoto H,Akase T,et al.Syndrome of inappropriate antidiuretic hormone secretion following adjuvant CDDP and 5-FU administration in a patient with esophageal carcinoma［J］.Gan To Kagaku Ryoho,2010,37(10):1945-1948.
[10]Kim HM,Bang S,Park JY,et al.Phase Ⅱ trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer［J］.Cancer Chemother Pharmacol,2009,63(3):535-541.
[11]Yoshioka H,Okamoto I,Morita S,et al.Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer:Updated results of the West Japan Oncology Group LETS Study［J］.Ann Oncol,2013,24(5):1326-1331.
[12]Tahara M,Araki K,Okano S,et al.Phase I trial of combination chemotherapy with docetaxel,cisplatin and S-1(TPS)in patients with locally advanced or recurrent/metastatic head and neck cancer［J］.Ann Oncol,2011,22(1):175-180.
[13]Nakamura K,Tahara M,Kiyota N,et al.Phase Ⅱ trial of concurrent chemoradiotherapy with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck：Japan Clinical Oncology Group Study(JCOG0706)［J］.Jpn J Clin Oncol,2009,39(7):460-463.
[14]Fujii M,Tomita K,Nishijima W,et al.Phase Ⅰ/Ⅱ study of S-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer［J］.Jpn J Clin Oncol,2010,40(3):214-221.
[15]Choi YJ,Chung JS,Shin HJ,et al.Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck［J］.J Laryngol Otol,2008,122(8):848-853.
[16]Ohashi T,Ohnishi M,Tanahashi S,et al.Efficacy and toxicity of concurrentchemoradiotherapy with nedaplatin and S-1 for head and neck cancer［J］.Jpn J Clin Oncol,2011,41(3):348-352.
[17]Yang Jianquan,Guo Wen,Wu Jingbo,et al.S-1 combined with concurrent radiotherapy for treatment of nasopharyngeal carcinoma：A Meta-analysis［J］.Sichuan Journal of Physiological Sciences,2015,37(4)：200-203.［杨健筌,郭文,吴敬波,等.替吉奥联合同步放疗治疗鼻咽癌的Meta分析［J］.四川生理科学杂志,2015,37(4):200-203.］
[18]Shirasaki T,Maruya S,Namba A,et al.Treatment results of chemotherapy with S-1 for head and neck cancer［J］.Gan To Kagaku Ryoho,2009,36(2):237-240.
[19]Gou Xiaoxia.Observation on the therapeutic effects of S-1 on the second-line treatment of advanced nasopharyngeal carcinoma［J］.Medical Information,2014,27(4):62.［苟小霞.替吉奥治疗二线晚期鼻咽癌临床疗效观察［J］.医学信息,2014,27(4):62.］
[20]Peng Peijian，Cheng Hua，Ou Xueqing,et al.Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum based chemotherapy:Multi-institutional retrospective analysis［J］.Drug Design Development and Therapy，2014,8:1083-1087.
[21]Peng Peijian,Ou Xueqing,Liao Hai,et al.Phase Ⅱ study of gemcitabine plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy［J］.Ther Adv Med Oncol,2016,8(3):153-159.

Memo

Memo:
-
Last Update: 2017-11-30